About this Research Topic
Chimeric Antigen Receptor (CAR) T-cell therapy represents a groundbreaking advancement in cancer treatment, particularly for hematological malignancies. Despite its potential to offer curative outcomes, the field faces significant challenges that hinder its widespread application. Current issues include the high costs and complexities associated with manufacturing CAR T-cells, especially in both autologous and allogeneic settings. The process involves intricate viral manufacturing and stability testing, which pose risks of systemic immunological and neurological reactions if cells are not properly cultured and screened. Recent studies have highlighted the need for improved targeting to minimize off-tumor effects and reduce cell-associated toxicities. Moreover, the phenomenon of antigen escape remains a formidable barrier, with over 80% of relapsed or refractory cases occurring in hematological cancers treated with CD19 and BCMA CAR T-cell therapies. While promising models for cost reduction and automation are emerging, there is a pressing need for innovative strategies to enhance the efficacy and safety of CAR T-cell therapies.
This Research Topic aims to address the critical challenges in developing a sustainable and cost-effective CAR T-cell therapy. The primary objectives include identifying promising models to reduce manufacturing costs, automating processes to minimize human error, and improving the therapeutic efficacy of CAR T-cells. Specific questions to be explored include how to decrease CAR immunogenicity, enhance tumor microenvironment infiltration, and prevent antigen escape. By focusing on these areas, the research seeks to advance the field towards more effective and safer cancer therapies.
To gather further insights in the realm of CAR T-cell therapy, we welcome articles addressing, but not limited to, the following themes:
• Innovations in viral delivery and cell engineering techniques.
• Strategies for reducing manufacturing costs and improving scalability.
• Approaches to minimize systemic immunological and neurological reactions.
• Development of humanized CARs to decrease immunogenicity.
• Methods to enhance CAR T-cell trafficking and infiltration in tumor microenvironments.
• Solutions to prevent antigen escape and improve long-term efficacy.
• Comparative analyses of autologous versus allogeneic CAR T-cell therapies.
This Research Topic aims to address the critical challenges in developing a sustainable and cost-effective CAR T-cell therapy. The primary objectives include identifying promising models to reduce manufacturing costs, automating processes to minimize human error, and improving the therapeutic efficacy of CAR T-cells. Specific questions to be explored include how to decrease CAR immunogenicity, enhance tumor microenvironment infiltration, and prevent antigen escape. By focusing on these areas, the research seeks to advance the field towards more effective and safer cancer therapies.
To gather further insights in the realm of CAR T-cell therapy, we welcome articles addressing, but not limited to, the following themes:
• Innovations in viral delivery and cell engineering techniques.
• Strategies for reducing manufacturing costs and improving scalability.
• Approaches to minimize systemic immunological and neurological reactions.
• Development of humanized CARs to decrease immunogenicity.
• Methods to enhance CAR T-cell trafficking and infiltration in tumor microenvironments.
• Solutions to prevent antigen escape and improve long-term efficacy.
• Comparative analyses of autologous versus allogeneic CAR T-cell therapies.
Keywords: CAR-T therapy, Biomarker, Ag, Ab, target, allogeneic, autologous, cell therapy, virus, innate and adoptive cell therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
